Prediction of ABO hemolytic disease of the newborn using pre- and perinatal quantification of maternal anti-A/anti-B IgG titer
Autor: | Bo Mølholm Hansen, Thomas Bergholt, Anette Kjærbye-Thygesen, Mette Line Donneborg, Finn Ebbesen, Morten Hanefeld Dziegiel, Per Albertsen, Grethe Risum Krog, Mette Kiel Smed, Kristian Vestergaard Jensen, Frederik Banch Clausen, Henriette Lorenzen |
---|---|
Rok vydání: | 2020 |
Předmět: |
congenital
hereditary and neonatal diseases and abnormalities Pregnancy Fetus medicine.medical_specialty biology business.industry Obstetrics Antibody titer medicine.disease Hemolysis 03 medical and health sciences Titer 0302 clinical medicine 030225 pediatrics ABO blood group system Pediatrics Perinatology and Child Health biology.protein Medicine Antibody business 030217 neurology & neurosurgery Screening procedures |
Zdroj: | Krog, G R, Donneborg, M L, Hansen, B M, Lorenzen, H, Clausen, F B, Jensen, K V, Kjærbye-Thygesen, A, Albertsen, P, Ebbesen, F, Bergholt, T, Smed, M K & Dziegiel, M H 2021, ' Prediction of ABO hemolytic disease of the newborn using pre-and perinatal quantification of maternal anti-A/anti-B IgG titer ', Pediatric Research, vol. 90, no. 1, pp. 74-81 . https://doi.org/10.1038/s41390-020-01232-5 |
ISSN: | 1530-0447 0031-3998 |
DOI: | 10.1038/s41390-020-01232-5 |
Popis: | Background: Hemolysis in fetus/newborns is often caused by maternal antibodies. There are currently no established screening procedures for maternal ABO antibodies harmful to fetus/newborn. We investigated the clinical significance, and predictive value of maternal anti-A/B titer for hyperbilirubinemia in ABO-incompatible newborns. Methods: We conducted a case–control study of blood group O mothers and their ABO-compatible (O) vs. -incompatible (A/B) newborns receiving phototherapy, and of ABO-incompatible newborns receiving phototherapy vs. no phototherapy. Newborn data and treatment modalities were recorded, and total serum bilirubin and hemoglobin were measured. Maternal anti-A/B immunoglobulin-γ (IgG) titers were measured prenatally and perinatally, and negative and positive predictive values (NPV, PPV) were calculated to assess the risk of developing hyperbilirubinemia requiring phototherapy. Results: We found a significantly higher maternal IgG antibody titer in the case group (p < 0.001). Maternal anti-A/B titers at first trimester had modest predictive values: NPV = 0.82 and PPV = 0.65 for neonatal hyperbilirubinemia; titers at birth improved the predictive values: NPV = 0.93 and PPV = 0.73. Newborn hemoglobin was significantly lower in incompatibles compared to compatibles (p = 0.034). Furthermore, increased anti-A/B IgG production during pregnancy was associated with hyperbilirubinemia and hemolysis in incompatible newborns. Conclusions: There was a significant association between maternal anti-A/B IgG titer and hyperbilirubinemia requiring treatment. Impact: Maternal anti-A/B IgG titer in the first trimester and at birth is predictive of hemolytic disease of the ABO-incompatible newborn.Increased IgG anti-A/B production throughout pregnancy in mothers to ABO-incompatible newborns developing hyperbilirubinemia contrasts a constant or reduced production in mothers to newborns not developing hyperbilirubinemia.Screening tools available in most immunohematology laboratories can identify clinically important IgG anti-A/B.Use of maternal samples taken at birth yielded NPV = 0.93 and PPV = 0.73. |
Databáze: | OpenAIRE |
Externí odkaz: |